Skip to main content

Table 4 Studies involving Linac-SBRT and CK-SBRT for early-stage NSCLC

From: High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study

  T factor (n) LC (%) OS (%) Dose Prescription Lung toxicity
Linac-SBRT
 Timmerman et al. [4] T1 (44) 3-year: 97.6 3-year: 55.8 54 Gy/3 Fr PTV D95 Grade 3: 4%
T2 (11)      
 Nagata et al. [5] T1 (169) Operable Operable 48 Gy/4 Fr Isocenter Operable
  3-year: 85.4 3-year: 76.5    Grade 3: 3%
  Inoperable Inoperable    Inoperable
  3-year: 87.3 3-year: 59.9    Grade 3: 8%
      Grade 4: 1%
 Koshy et al. [21] T1 (334) NA 3-year: 50 48–60 Gy/3–4 Fr NA NA
T2 (164)   5-year: 30    
 Matsuo et al. [25] T1 (73) 3-year: 86.8 3-year: 58.6 48 Gy/4 Fr Isocenter Grade 3: 3%
T2 (28)   5-year: 46.7    
CK-SBRT
 Bahig et al. [10] T1 (123) 2-year: 96 2-year: 87 40–60 Gy/3–5 Fr PTV D95 Grade 3: 1%
T2 (27)     75% isodose Grade 5: 2% (with IPF)
 Heal et al. [11] T1 (63) 2-year: 94 3-year: 37 50–60 Gy/3–5 Fr NA Grade 3: 2%
T2 (37) 3-year: 84     
 van der Voort van Zyp et al. [12] T1 (39) 2-year 1-year: 83 45 or 60 Gy/3 Fr PTV D95 Grade 3: 4%
T2 (31) 45 Gy: 78 2-year: 62   70–85% isodose  
  60 Gy: 96     
 Present study T1a/b (61) 2-year: 97 2-year: 90 54–60 Gy/3 Fr GTV D99 Grade 3: 1%
T1c (30)     70–80% isodose  
T2 (5)      
  1. Linac-SBRT linear accelerator-based stereotactic body radiotherapy, CK-SBRT CyberKnife®-based stereotactic body radiotherapy, NSCLC non-small cell lung carcinoma, PTV planning target volume, NA not available, IPF idiopathic pulmonary fibrosis, GTV gross tumor volume, Fr fractions